Overview
Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2019, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years, across the globe. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, are still considered as the current standard of care. However, their efficacy is severely limited, especially when it comes to treating late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, are known to have a significant adverse impact on patients’ quality of life.
There are several targeted anti-cancer therapies that are available in the market and many are presently under development. Of these, immune checkpoint therapies have shown a lot of promise as viable and potent treatment options, capable of preventing tumor cells from evading immune surveillance. In 2011, Bristol-Myers Squibb’s Yervoy® (ipilimumab), an anti-CTLA-4 monoclonal antibody, became the first FDA approved immune checkpoint inhibitor which was designed for the treatment of metastatic melanoma. Yervoy®, along with other first generation immune checkpoint inhibitors (targeting PD-1/PD-L1 and CTLA-4), soon demonstrated the ability to substantially prolong the lives of patients suffering from advanced stage tumors. However, despite the success of PD 1/PD-L1 inhibitor drugs, there was a notable amount of resistance to treatment reported in certain groups of patients, which compromised the therapeutic potential of this relatively novel class of therapeutics.
Over the years, significant strides have been made in immune checkpoint modulation research, revealing several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are now being exploited for development of next generation immune checkpoint-based therapies. Moreover, clinical studies of combinatorial immune checkpoint blockade/co-stimulation, involving the newly identified checkpoints and known immune checkpoint inhibitor therapies, have demonstrated the potential to further augment therapeutic benefits. It is worth highlighting that these molecules have also shown to be capable of regulating immune tolerance and preventing/treating autoimmune disorders. Therefore, backed by promising clinical results and expanding applicability of therapies being investigated in late stages of development, the immune checkpoint inhibitors and stimulators market is poised to witness substantial growth in the foreseen future.
Scope of the Report
The “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
In addition to other elements, the study includes:
- A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical/discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).
- A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors/collaborators (in terms of number of trials conducted), trial focus, type of target, target indication(s), target therapeutic area(s), enrolled patients population and regional distribution.
- Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
- An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, popular target immune checkpoints, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of target immune checkpoints and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as grant amount, support period, type of grant application and number of disease indications under investigation.
- An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to affiliated technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals.
- An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.
- An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio.
One of the key objectives of the report was to estimate the existing market size and the future opportunity for next generation immune checkpoint inhibitors and stimulators, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of next generation checkpoint modulator therapies and their likely selling price, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (colorectal cancer, head and neck cancer, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, primary Sjögren's syndrome and systemic lupus erythematosus/lupus nephritis) [B] key immune checkpoint targets (B7-H3, CD38, CD40, CD47 and ICOS [C] mechanisms of action (inhibitory and costimulatory), [D] therapeutic modalities used (antibody fragment, monoclonal antibody and small molecule), [E] type of therapy (monotherapy, combination therapy and both), [F] route of administration (intravenous, subcutaneous and intracerebroventricular) and [G] key geographical regions (US, EU5, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- AbClon
- Abeome
- ABL Bio
- Abpro
- Acerta Pharma
- Acrus Biosciences
- Actinium Pharmaceuticals
- Adaptive Biotechnologies
- AdoRx Therapeutics
- Aduro Biotech
- Advaxis
- Agenus
- Agios Pharmaceuticals
- Alexion Pharmaceuticals
- Allergan
- Alligator Bioscience
- Alpine Immune Sciences
- ALX Oncology
- Amgen
- Angel Therapeutics
- Anvil Biosciences (The company has been acquired)
- Apexigen
- Apogenix
- Aptevo Therapeutics
- Arch Oncology
- Arcus Biosciences
- ArQule
- Astellas Pharma
- Astex Pharmaceuticals
- AstraZeneca
- Atridia
- Aurigene Discovery Technologies
- Avacta Life Sciences
- Bach BioSciences
- BeiGene
- BinDeBio Group
- BIOCAD
- Biodextris
- BioNTech
- Bio-Techne
- Black Belt Therapeutics
- BliNK Biomedical
- bluebird bio
- Boehringer Ingelheim
- Boston Medical Center
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Calithera Biosciences
- CALIXAR
- CASI Pharmaceuticals
- Catalent Biologics
- Celgene
- Celldex Therapeutics
- Center for Applied Medical Research
- Centrose
- Checkpoint Therapeutics
- China National Biotec Group
- CleveXel Pharma
- Columbia University Irving Medical Center
- Compass Therapeutics
- Compugen
- Corvus Pharmaceuticals
- Crescendo Biologics
- CStone Pharmaceuticals
- Curis
- D5Pharma
- Daiichi Sankyo
- Distributed Bio
- DNAtrix
- Domain Therapeutics
- Dova Pharmaceuticals
- Dualogics
- Eisai
- Eli Lilly
- Elpiscience Biopharma
- ELSALYS BIOTECH
- EMulate Therapeutics
- EpicentRx
- FF Pharmaceuticals
- Five Prime Therapeutics
- Forty Seven
- Fred Hutchinson Cancer Research Center
- F-star
- Gateway Biologics
- Genentech
- Genmab
- Genomics Medicine Ireland
- Genosco
- GigaGen
- Gilead Sciences
- Glaxosmithkline
- Glenmark
- Glycotope
- Hanmi Pharmaceutical
- HanX Biopharmaceuticals
- Heat Biologics
- Hrain Biotechnology
- Hummingbird Bioscience
- IGM Biosciences
- I-Mab Biopharma
- Immatics
- ImmuneOncia Therapeutics
- ImmuneOnco Biopharmaceuticals
- ImmuNext
- Impetis Biosciences
- Incyte
- Inhibrx
- Innate Pharma
- Innovent Biologics
- Institute for Research in Biomedicine
- InteRNA Technologies
- International Myeloma Foundation
- IO Biotech
- iOnctura
- iTeos Therapeutics
- Janssen Pharmaceuticals
- Jiangxi Qingfeng Pharmaceutical
- JN Biosciences
- Johns Hopkins University
- Johnson & Johnson
- Juventas Cell Therapy
- KAHR Medical
- Kiniksa Pharmaceuticals
- Kite Pharma
- Kleo Pharmaceuticals
- Kymab
- Kyowa Hakko Kirin
- Leap Therapeutics
- LG Chem
- LifeArc
- Lynkcell
- Macrocure
- MacroGenics
- Marino Biotechnology
- Massachusetts General Hospital
- MedImmune
- Merck
- Merus
- Moderna
- Molecular Partners
- Molecular Templates
- Momenta Pharmaceuticals
- Morphiex
- MorphoSys
- Mount Sinai Innovation Partners
- Nanjing Chia Tai Tianqing
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Dental and Craniofacial Research
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Neurological Disorders
- NavarraBiomed-Biomedical Research Centre
- Navigen
- Neon Therapeutics
- NewLink Genetics
- NextCure
- Novartis
- Novimmune
- Numab Therapeutics
- Ogeda
- OncoArendi Therapeutics
- Oncotelic
- Ono Pharmaceutical
- ORIC Pharmaceuticals
- OSE Immunotherapeutics
- Palobiofarma
- Pandion Therapeutics
- Paradigm Shift Therapeutics
- Parker Institute for Cancer Immunotherapy
- Pascal Biosciences
- Peloton Therapeutics
- PeptiDream
- PersonGen BioTherapeutics (Suzhou)
- Pfizer
- PharmAbcine
- Pieris Pharmaceuticals
- Pinze Lifetechnology
- Potenza Therapeutics
- PsiOxus Therapeutics
- Roche
- Rubius Therapeutics
- Sanofi
- Sanquin
- Seattle Genetics
- Shanghai GeneChem
- Shattuck Labs
- Shire
- Sorrento Therapeutics
- Stanford University
- Surface Oncology
- Sutro Biopharma
- Swedish Orphan Biovitrum
- Symphogen
- Synthon International Holding
- Syros Pharmaceuticals
- Takeda Pharmaceutical
- Tarus Therapeutics
- Tempest Therapeutics
- TESARO
- TG Therapeutics
- The University of Texas MD Anderson Cancer Center
- Tottori University
- TRACON Pharmaceuticals
- Trellis Biosciences
- TRIGR Therapeutics
- Trillium Therapeutics
- Tsinghua University
- Union Stem Cell & Gene Engineering
- University of California San Francisco
- University of California, Los Angeles
- University of California, San Diego
- University of Minnesota
- Vall d’Hebron Institute of Oncology
- Valo Therapeutics
- Viela Bio
- ViraTherapeutics
- Vivoryon Therapeutics
- Washington University
- Waterstone Hanxbio
- Xencor
- XOMA
- Y-Biologics
- Yale Cancer Center
- Yale University
- Y-mAbs Therapeutics
- Yuhan Pharmaceuticals
- Zai Lab
- Zymeworks
Methodology
LOADING...